CCM Therapy for Heart Failure
(AIM HIGHer Trial)
Trial Summary
What is the purpose of this trial?
This trial tests a device that helps the heart pump better in patients with moderate heart failure. It targets those whose heart's pumping ability is moderately reduced. The device works by giving the heart small electrical boosts. Several new devices for the treatment of heart failure patients have been introduced and are increasingly used in medical practice or are under evaluation.
Will I have to stop taking my current medications?
The trial requires that participants stay on a stable dose of oral loop diuretics for at least 30 days before joining. It doesn't specify if you need to stop other medications, so it's best to discuss with the trial team.
What data supports the effectiveness of this treatment for heart failure?
Research shows that Cardiac Contractility Modulation (CCM) therapy, delivered by the Optimizer Smart System, is safe and can improve exercise tolerance and quality of life in heart failure patients. It is especially beneficial for those who do not qualify for other therapies, like cardiac resynchronization therapy (CRT), and has been shown to work without increasing oxygen demand.12345
Is Cardiac Contractility Modulation Therapy safe for humans?
How is Cardiac Contractility Modulation Therapy different from other heart failure treatments?
Cardiac Contractility Modulation (CCM) Therapy, delivered by the Optimizer Smart Mini System, is unique because it uses electrical signals to improve heart function in patients who do not qualify for other device therapies like cardiac resynchronization therapy (CRT). It is specifically designed for heart failure patients with a normal QRS duration and can be used in those who do not respond to CRT, offering a new option for improving heart performance and quality of life.12347
Eligibility Criteria
Adults diagnosed with symptomatic heart failure, who have been hospitalized for it or needed urgent IV therapy in the past year, and have a left ventricular ejection fraction (LVEF) between 40% and 60%. They must be on stable diuretic treatment. Exclusions include pregnancy plans during the study, certain heart rates, complex heart conditions, inability to walk specific distances, recent acute heart issues or procedures.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Testing and Implantation
All eligible subjects will undergo baseline testing and be implanted with the Optimizer System
Treatment Part I
CCM therapy is evaluated for safety and effectiveness based on functional capacity and health status
Treatment Part II
CCM therapy is evaluated for safety and effectiveness based on clinical outcome data
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System (Cardiac Contractility Modulation)
- OPTIMIZER™ Smart Mini System (Cardiac Contractility Modulation)
- Sham Therapy (Device)
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System is already approved in United States, European Union for the following indications:
- Heart failure in NYHA Class III patients with LVEF ranging from 25% to 45%, who remain symptomatic despite guideline directed medical therapy and are not indicated for CRT
- Heart failure in NYHA Class III patients with LVEF ranging from 25% to 45%, who remain symptomatic despite guideline directed medical therapy and are not indicated for CRT